Fellowship, The National Cancer Institute (NCI), Bethesda, Maryland
Internship, Internal Medicine, Tulane University School of Medicine, New Orleans, Louisiana
Internship, University of Pennsylvania
MD, Tulane University School of Medicine, New Orleans, Louisiana
Dr. Sartor received his MD from Tulane University School of Medicine with honors in 1982. After an internship at the University of Pennsylvania, he trained in internal medicine at Tulane Medical School. After completing a fellowship at the National Cancer Institute (NCI) in Bethesda, Maryland in 1989, he served until 1993 as a senior investigator at the NCI and began focusing on novel therapeutics for advanced prostate cancer patients. Dr. Sartor returned to Louisiana in 1993 to serve as an Associate Professor at the LSU Medical School in Shreveport and then moved to the LSU Health Sciences Center in New Orleans in 1998 as the Patricia Powers Strong Professor of Oncology, the Stanley S. Scott Cancer Center Director, and the Hematology/Oncology Section Chief. He was the Co-Director of the Louisiana Cancer Research Consortium, starting at its legislative inception in 2002. In March 2006, he left LSU to join the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute and the Harvard Medical School. In January 2008, Dr. Sartor joined Tulane University as the C. E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology.
An internationally recognized expert in prostate cancer, Dr. Sartor’s interests have focused broadly on prostate cancer, predominantly in those patients who failed initial therapies. His publications range from genetic studies on prostate cancer to clinical trials involving novel agents. He has been a lead author on two studies pivotal for FDA drug approval in prostate cancer and has been the PI or co-PI on a number of prospective international clinical trials evaluating new therapies for patients with advanced prostate cancer.
Having published over 500 scholarly articles and having served as the past Chairman of the Department of Defense Prostate Integration Panel, Dr. Sartor, in addition to being the C.E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology, is the Medical Oncology Chair of the GU Committee of the NRG, the Assistant Dean for Oncology at Tulane University School of Medicine, the Medical Director of the Tulane Cancer Center, and the Editor-in-Chief of the peer-reviewed journal, Clinical Genitourinary Cancer. In addition, he is currently a member of the NCI Board of Scientific Counselors (Clinical Sciences and Epidemiology).
Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wootten A, Walsh PC, Costello AJ. The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.BJU Int. 2013 Nov 8. doi: 10.1111/bju.12556. [Epub ahead of print] No abstract available.
Parker C, Sartor O. Radium-223 in prostate cancer. N Engl J Med. 2013 Oct 24;369(17):1659-60. doi: 10.1056/NEJMc1310231. No abstract available.
Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O. Castration-resistant prostate cancer: Adaptive responses in the androgen axis. Cancer Treat Rev. 2013 Sep 14. pii: S0305-7372(13)00200-4. doi: 10.1016/j.ctrv.2013.09.011. [Epub ahead of print]
Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, de Bono J, Sartor O. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013 Nov 20;105(22):1729-37. doi: 10.1093/jnci/djt280. Epub 2013 Oct 17.
Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, Solomon NC, Small EJ. Prostate-specific antigen changes as surrogate for overall survival in men with etastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2013 Nov 1;31(31):3944-50. doi: 10.1200/JCO.2013.50.3201. Epub 2013 Oct 7.
Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol. 2014 Feb;65(2):289-99. doi: 10.1016/j.eururo.2013.08.008. Epub 2013 Aug 11.
Sartor AO. Surveillance for prostate cancer: are the proceduralists running amok? Oncology (Williston Park). 2013 Jun;27(6):523, 593. No abstract available.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O, ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.
Valicenti RK, Thompson I Jr, Albertsen P, Davis BJ, Goldenberg SL, Wolf JS, Sartor O, Klein E, Hahn C, Michalski J, Roach M 3rd, Faraday MM. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. American Society for Radiation Oncology/American Urological Association. Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):822-8. doi: 10.1016/j.ijrobp.2013.05.029. Review.
View more publications on PubMed